EX-99.2 3 tm2323017d2_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

1 Powered by Technology. Built by Doctors. For Patients. Apollo Medical Holdings (NASDAQ: AMEH) Second Quarter 2023 Earnings Call Supplement August 7, 2023

Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about t he Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, int egration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward - looking terms such as “anticipa te,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envisi on, ” “intend,” “continue,” “target,” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other simila r o r comparable words, phrases or terminology. Forward - looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward - looking statements due to risks, uncerta inties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Commission (the “SEC”), including without limitation the risk factors discussed in the Company's Annu al Report on Form 10 - K for the year ended December 31, 2022, and subsequent Quarterly Reports on Form 10 - Q. Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or imp lie d in any forward - looking statements, you should not place undue reliance on any such forward - looking statements. Any forward - looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any ob lig ation to update any forward - looking statement, as a result of new information, future events or otherwise. 2

15 * ma naged IPAs and groups 1.3M managed lives Company Overview 3 12,000+ contracted physicians 25+ years in operation ApolloMed is a technology - powered, value - based healthcare platform that enables the delivery of high - quality, coordinated, efficient, and accessible care for all through the following business segments: ​ Care Enablement delivers an integrated clinical and administrative platform to enable payers and providers in the delivery of high - quality, value - based care. Care Partners enables aligned providers to participate in high - performing, risk - bearing organizations.​ Care Delivery provides patient - centric clinical operations, including primary care, multi - specialty, and ancillary services.​ ApolloMed At - A - Glance Ticker NASDAQ: AMEH Headquarters Alhambra, California Recent Stock Price (as of 8/4/2023) $37.67 Market Cap (as of 8/4/2023) $2.2 billion Common Shares Outstanding* (as of 8/1/2023) 57.6 million Book Value Per Common Share $9.94 TTM Revenues $1.30 billion IPA: independent physician association *As of 6/30/2023 *Includes 10.6 million in treasury shares Information as of 6/30/2023 unless otherwise noted

Highlights 4 Operational updates Revenue $348.2M 29% Net income attr. to AMEH $13.2M 10% EPS – diluted $0.28 8% Adj. EBITDA* $35.8M 44% *See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more infor mation. Please note that beginning the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude addbacks relat ed to provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. • Formed a long - term partnership with a primary care group in California with over 50 providers • Expected to be onboarded onto Care Enablement (CE) platform by September 1, 2023 • Entered definitive agreement to acquire assets relating to Texas Independent Providers, a primary care service provider serving patients in Houston metro with a network of over 120 providers • Transaction expected to close in Q3 2023 and providers onboarded onto CE platform by end of 2023 • Formed partnership with IntraCare , an operator of a value - based primary care network with over 425 providers in Texas & Oklahoma • Expected to be onboarded onto CE platform by end of 2023 Q2 2023 financial results % vs. prior - year period

Historical Financial Profile 5 2021 Adjusted EBITDA benefitted from tailwinds of lower utilization during the COVID - 19 pandemic; Return to pre - pandemic utilization in 2022 and 2023 $561 $687 $774 $1,144 $1,300 - $1,500 Historical Revenue Growth ($ in millions) 2019 2020 2021 2022 2023 26% CAGR from 2019 - 2023E $54.2 $102.8 $133.5 $140.0 ($ in millions) Historical Adjusted EBITDA (1) 27% CAGR from 2019 - 2023E 2019 2020 2021 2022 2023 $120.0 - $160.0 (1) See “Use of Non - GAAP Financial Measures” slide for more information

Tax Restatement 6 Note: 2019 was immaterial and therefore no restatement As Restated As Original $ Change $ in 000s except per share data 2022 2021 2020 2022 2021 2020 2022 2021 2020 Income before provision for income tax $ 86,616 77,748 178,427 $ 86,616 77,748 178,427 $ - - - Provision for income tax 40,875 31,693 56,344 36,085 28,454 56,107 4,790 3,239 237 Net income 45,741 46,055 122,083 50,531 49,294 122,320 (4,790) (3,239) (237) Net income (loss) attributable to non - controlling interest 570 (22,868) 84,395 1,482 (24,564) 84,454 (912) 1,696 (59) Net income attributable to Apollo Medical Holdings 45,171 68,923 37,688 49,049 73,858 37,866 (3,878) (4,935) (178) Earnings per share – basic $ 1.00 1.57 1.03 $ 1.09 1.69 1.04 $ (0.09) (0.12) (0.01) Earnings per share – diluted $ 0.99 1.52 1.01 $ 1.08 1.63 1.01 $ (0.09) (0.11) - Please see Form 8 - K filed on August 7, 2023, for more details. In summary: • The Company did not appropriately account for the income tax impact associated with certain intercompany dividends and also neglected to include certain loss generating entities in certain consolidated tax filing groups. • Going forward, we are evaluating changes to our tax structure to reduce the current effective tax rate and amount of cash tax es. • We expect to have this put in place by the fourth quarter of 2023, which we believe will result in a normalized tax rate movi ng forward. • There was no impact on GAAP and non - GAAP measures the Company reports, including revenue, gross profit, pretax income from continuing operations, EBITDA, or Adjusted EBITDA, in past and go - forward periods as a result of this tax - related restateme nt.

Summary of Selected Financial Results 7 Three Months Ended June 30, Six Months Ended June 30, $ in 000s except per share data 2023 2022 (restated) 2023 (restated) 2022 (restated) Revenue Capitation, net $ 300,549 $ 227,623 $ 600,753 $ 449,682 Risk pool settlements and incentives 21,121 18,793 33,583 36,868 Management fee income 12,493 9,984 22,389 20,457 Fee - for - service, net 13,262 11,740 25,324 22,835 Other income 1,784 1,557 3,404 3,112 Total revenue 348,209 269,697 685,453 532,954 Total expenses 321,180 254,315 636,050 491,360 Income from operations 27,029 15,382 49,403 41,594 Net income 17,482 11,277 29,970 22,727 Net income (loss) attributable to noncontrolling interests 4,312 (673) 3,668 (2,987) Net income attributable to ApolloMed $ 13,170 $ 11,950 $ 26,302 $ 25,714 Earnings per share – diluted $ 0.28 $ 0.26 $ 0.56 $ 0.56 EBITDA $ 36,044 $ 22,413 $ 60,007 $ 46,082 Adjusted EBITDA $ 35,772 $ 24,906 $ 65,599 $ 59,266

Segment Results 8 $ in 000s Care Enablement Care Partners Care Delivery Other Intersegment Elimination Corporate Costs Consolidated Total Total revenues $ 34,975 325,246 26,718 157 (38,887) - 348,209 % change vs prior year quarter 18% 31% 14% 29% Cost of services 15,162 292,119 22,523 70 (36,988) - 292,876 General and administrative expenses (1) 12,175 5,298 3,626 926 (2,933 ) 9,212 28,304 Total expenses 27,337 297,417 26,149 996 (39,931) 9,212 321,180 Income (loss) from operations $ 7,638 27,829 569 (839) 1044 (2) (9,212) 27,029 % change vs prior year quarter 4% 250% (82%) 76% For the three months ended June 30, 2023 (1) Balance includes general and administrative expenses and depreciation and amortization . (2) Income from operations for the intersegment elimination represents rental income from segments renting from other segments. R ent al income is presented within other income, which is not presented in the table.

Revenue Breakdown 9 For the six months ended June 30, 2023 Revenue by Line of Business Business Mix By Payer Type 87.6% 4.9% 3.3% 3.7% 0.5% Capitation, net Risk Pool Settlements & Incentives Management Fee Income Fee-for-service, net Other Income 64% 20% 12% 4% Medicare Medicaid Commerical Other Third Parties

Balance Sheet Highlights 10 $ in millions 6/30/2023 12/31/2022 $ Change % Change Cash and cash equivalents and investments in marketable securities* $297.7 $293.6 $4.1 1.0% Working capital $280.0 $279.5 $0.5 0.2% Total stockholders’ equity $566.0 $542.6 $23.4 4.3% *Excluding restricted cash

2023 Guidance 11 $ in millions, except for per share information Actual YE 2022 Results 2023 Guidance Range Total Revenue $1,144.2 $1,300.0 - $1,500.0 Net Income (1) $50.5 $49.5 - $71.5 EBITDA (1,2) $110.1 $89.5 - $129.5 Adjusted EBITDA (2) $140.0 $120.0 - $160.0 EPS – Diluted $1.08 $0.95 - $1.20 (1) Net income and EBITDA forecast includes the impact of APC excluded assets, which assume no change in value. (2) See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Income to EBITDA and Adjust ed EBITDA” and “Use of Non - GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward - Looking Statements” on slide 2.

Reconciliation of Net Income to EBITDA and Adjusted EBITDA 12 (1) See “Use of Non - GAAP Financial Measures” slide for more information. (2) Other, net for the three and six months ended June 30, 2023, relates to non - cash changes in the fair value of the Company’s fina ncing obligations to purchase the remaining equity interest, changes in the fair value of its contingent liabilities, and changes in the fair value of the Comp any ’s Collar Agreement. (3) Adjusted EBITDA under the historical method for the three and six months ended June 30, 2023, was $36.9 million and $75.1 mil lio n, respectively. See “Use of Non - GAAP Financial Measures” slide for additional information on change of methodology. ($ in millions) 2023 2022 2023 2022 Net income $ 17.5 $ 11.3 $ 30.0 $ 22.7 Interest expense 3.6 1.9 6.9 2.9 Interest income (3.3) (0.4) (6.3) (0.5) Provision for income taxes 14.0 5.4 20.9 12.2 Depreciation and amortization 4.2 4.4 8.5 8.7 EBITDA (1) $ 36.0 $ 22.4 $ 60.0 $ 46.1 Income from equity method investments $ (0.3) $ (0.2) $ (0.5) $ (0.3) Other, net (2) (1.6) - (0.2) - Stock-based compensation 4.2 3.9 7.7 7.0 APC excluded assets costs (2.6) (1.2) (1.3) 6.5 Adjusted EBITDA (1,3) $ 35.8 $ 24.9 $ 65.6 $ 59.3 Three Months Ended June 30, Six Months Ended June 30,

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA 13 (1) See “Use of Non - GAAP Financial Measures” slide for more information. ($ in millions) Low High Net income $ 49.5 $ 71.5 Interest expense 1.0 1.0 Provision for income taxes 23.0 38.0 Depreciation and amortization 16.0 19.0 EBITDA (1) $ 89.5 $ 129.5 Income from equity method investments $ (0.8) $ (0.8) Other, net 3.3 3.3 Stock-based compensation 16.0 16.0 APC excluded assets costs 12.0 12.0 Adjusted EBITDA (1) $ 120.0 $ 160.0 Year Ending December 31, 2023

14 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Revenue Capitation, net $ 600.8 - 600.8 $ 449.7 - 449.7 Risk pool settlements and incentives 33.6 - 33.6 36.9 - 36.9 Management fee income 22.4 - 22.4 20.5 - 20.5 Fee - for - service, net 25.3 - 25.3 22.8 - 22.8 Other income 3.4 - 3.4 3.1 - 3.1 Total revenue 685.5 - 685.5 533.0 - 533.0 Total operating expenses 636.0 1.3 634.8 491.3 1.6 489.7 Income (loss) from operations 49.4 (1.3) 50.7 41.7 (1.6) 43.3 Total other income (expense), net 1.5 2.1 (0.6) (6.7) (8.5) 1.8 Net income (loss) $ 30.0 0.9 29.1 $ 22.8 (10.1) 32.9 Summary of Selected Financial Results – Breaking Out Excluded Assets (1) Includes AP Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns the as set but not the right to the dividends associated with those assets. (1)

15 Summary Balance Sheet – Breaking Out Excluded Assets $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Current assets Cash and cash equivalents $ 294.2 13.1 281.1 $ 288.0 30.2 257.8 Investments in marketable securities 3.8 1.1 2.7 5.6 4.5 1.1 Receivables, net 66.9 - 66.9 49.6 - 49.6 Receivables - related parties and loan receivable - related party 82.8 - 82.8 67.2 - 67.2 Other receivables, prepaid expenses and other current assets 17.3 1.2 16.1 17.6 0.8 16.8 Income taxes receivable - - - - (1.1) 1.1 Total current assets 465.0 15.4 449.6 428.0 34.4 393.6 Non-current assets Land, property, and equipment, net 123.9 116.9 7.0 108.5 101.3 7.2 Goodwill and intangibles 348.4 - 348.4 346.0 - 346.0 Loan receivable and loan receivable - related parties, net of current portion - - - - - - Income taxes receivable, non-current 15.9 - 15.9 15.9 - 15.9 Investments in other entities and privately held entities 48.7 32.2 16.5 41.2 27.6 13.6 Other assets and right-of-use assets 25.1 4.2 20.9 26.5 3.2 23.3 Total non-current assets 562.0 153.3 408.7 538.1 132.1 406.0 Total assets $ 1,027.0 168.7 858.3 $ 966.1 166.5 799.6 June 30, 2023 December 31, 2022 (1) Includes AP Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns the as set but not the right to the dividends associated with those assets. (1) (1)

16 Summary Balance Sheet – Breaking Out Excluded Assets (continued) $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Current liabilities Fiduciary payable, accounts payable and accrued liabilities $ 58.5 0.7 57.8 $ 57.7 2.8 54.9 Medical liabilities 100.0 - 100.0 81.3 - 81.3 Income taxes payable 19.6 1.1 18.5 4.3 - 4.3 Dividend payable 0.6 - 0.6 0.7 - 0.7 Finance and operating lease liabilities 3.6 0.1 3.5 4.2 - 4.2 Current portion of long-term debt 2.6 0.6 2.0 0.6 0.6 - Total current liabilities 184.9 2.5 182.4 148.8 3.4 145.4 Non-current liabilities Deferred tax liability 12.4 0.9 11.5 14.2 0.9 13.3 Finance and operating lease liabilities, net of current portion 19.0 0.90 18.1 21.2 - 21.2 Other long-term liabilities 21.4 - 21.4 20.3 - 20.3 Long-term debt, net of current portion and deferred financing costs 205.1 27.9 177.2 203.4 26.6 176.8 Total non-current liabilities 257.9 29.7 228.2 259.1 27.5 231.6 Total liabilities 442.8 32.2 410.6 407.9 30.9 377.0 Total mezzanine equity and stockholder's equity $ 584.2 136.5 447.1 $ 558.2 135.6 422.6 June 30, 2023 December 31, 2022 (1) Includes AP Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns the as set but not the right to the dividends associated with those assets. (1) (1)

Summary Cash Flow Statement – Breaking Out Excluded Assets 17 $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Cash flows from operating activities Net income $ 30.0 0.9 29.1 $ 22.7 (10.1) 32.8 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization $ 8.5 0.8 7.7 $ 8.7 0.5 8.2 Amortization of debt issuance cost 0.5 - 0.5 0.5 - 0.5 Share-based compensation 7.7 - 7.7 7.0 - 7.0 Unrealized loss on investments 5.5 3.5 2.0 13.7 11.3 2.4 Gain on sales of investment - - - (2.3) - (2.3) Loss (income) from equity method investments, net (5.2) (4.7) (0.5) (2.9) (0.1) (2.8) Unrealized gain on interest rate swaps - - - (2.8) (2.8) - Deferred tax (3.7) - (3.7) 3.4 - 3.4 Changes in operating assets and liabilities, net of acquisition amounts: Receivables, net, receivable, net - related parties, other receivable, prepaid expenses and other current assets, right of use assets, other assets, fiduciary accounts payable, medical liabilities, and operating lease liabilities (22.4) (0.5) (21.9) (15.1) 0.7 (15.8) Accounts payable and accrued liabilities (2.9) (2.1) (0.8) 14.2 (0.1) 14.3 Income taxes payable 15.3 - 15.3 (14.0) - (14.0) Net cash provided by (used in) operating activities $ 33.3 (2.1) 35.4 $ 33.1 (0.6) 33.7 June 30, 2022June 30, 2023 (1) Includes AP Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns the as set but not the right to the dividends associated with those assets. (1) (1)

Summary Cash Flow Statement – Breaking Out Excluded Assets (continued) 18 $ in millions ApolloMed Consolidated Excluded Assets ApolloMed Assets ApolloMed Consolidated Excluded Assets ApolloMed Assets Cash flows from investing activities Payments for business and asset acquisition, net of cash acquired $ 0.4 - 0.4 $ (0.9) - (0.9) Proceeds from repayment of loans receivable - related parties 2.1 - 2.1 4.0 4.0 - Purchase of marketable securities (2.0) - (2.0) $ (1.8) - (1.8) Purchase of investments - privately held (2.0) - (2.0) - - - Purchase of investments - equity method (0.3) - (0.3) - - - Proceeds from sale of marketable securities - - - 6.5 (0.1) 6.6 Distribution from investments - equity method - - - 0.4 0.4 - Contribution to investment - equity method - - - (1.7) (1.7) - Purchases of property and equipment -17.4 -16.4 -1.0 -18.8 -17.8 -1.0 Net cash (used in) provided by investing activities (19.2) (16.4) (2.8) (12.3) (15.2) 2.9 Cash flows from financing activities Dividends paid $ (0.8) - (0.8) $ (12.6) (10.0) (2.6) Repayments on long-term debt (0.3) (0.3) - (0.2) (0.2) - Payment of finance lease obligations (0.3) - (0.3) (0.3) - (0.3) Proceeds from exercise of stock options and warrants 1.3 - 1.3 1.7 - 1.7 Repurchase of common stock - - (9.5) - (9.5) Repurchase of treasury shares (9.5) - (9.5) - - - Purchase of non-controlling interest (0.1) - (0.1) (0.2) - (0.2) Proceeds from sale of non-controlling interest - - - - - - Borrowings on loans 1.7 1.6 0.1 1.2 0.6 0.6 Amounts due from affiliates - - - - (16.6) 16.6 Net cash (used in) provided by financing activities $ (8.0) 1.3 (9.3) $ (19.9) (26.2) 6.3 Net change in cash and cash equivalents 6.1 (17.2) 23.3 1.1 (41.9) 43.0 Cash and cash equivalents at beginning of year $ 288.0 30.2 257.8 $ 233.1 62.5 170.6 Cash and cash equivalents at end of year $ 294.1 13.0 281.1 $ 234.2 20.6 213.6 June 30, 2022June 30, 2023(1) Includes AP Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns the as set but not the right to the dividends associated with those assets. (1) (1)

Use of Non - GAAP Financial Measures This presentation contains the non - GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable fin ancial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. These measures are not in acc ordance with, or alternatives to GAAP, and may be different from other non - GAAP financial measures used by other companies. The Company uses Adju sted EBITDA as a supplemental performance measure of our operations, for financial and operational decision - making, and as a supplemental means o f evaluating period - to - period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and am ortization, excluding income or loss from equity method investments, non - recurring transactions, stock - based compensation, and APC excluded assets costs. Beg inning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payme nts and losses from recently acquired IPAs, which it believes to be more reflective of its business. The Company believes the presentation of these non - GAAP financial measures provides investors with relevant and useful informati on, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recogniz ed because of non - core or non - recurring financial information. When GAAP financial measures are viewed in conjunction with non - GAAP financial measures, in vestors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non - GAAP financial measu res are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecas tin g future periods. Non - GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To t he extent this release contains historical or future non - GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non - GAAP measures is provided above. 19

20 For inquiries, please contact: ApolloMed Investor Relations (626) 943 - 6491 investors@apollomed.net Carolyne Sohn, The Equity Group (408) 538 - 4577 csohn@equityny.com